Key Takeaways
- The semaglutide weight loss dosing chart steps from 0.25 mg in week 1 to 2.4 mg by week 17, escalating every 4 weeks.
- At a 2.5 mg/mL compounded concentration, those doses translate to 10, 20, 40, 68, and 96 units on a U-100 insulin syringe.
- Brand-name Wegovy uses a fixed-dose pen at the same milligram amounts.
- Maintenance begins at week 17.
- Most patients can adjust the schedule by 2 to 4 weeks at any step if side effects are heavy, so the practical timeline runs 16 to 24 weeks before reaching 2.4 mg.
Direct answer (40-60 words)
The semaglutide weight loss dosing chart steps from 0.25 mg in week 1 to 2.4 mg by week 17, escalating every 4 weeks. At a 2.5 mg/mL compounded concentration, those doses translate to 10, 20, 40, 68, and 96 units on a U-100 insulin syringe. Brand-name Wegovy uses a fixed-dose pen at the same milligram amounts.
Table of contents
- The 30-second answer
- The standard 5-step semaglutide titration schedule
- Full dosage chart in mg, units, and mL
- Why titration goes slowly
- How concentration changes the unit count
- Reading your vial label correctly
- Pen doses (Wegovy) vs vial doses (compounded)
- When to hold or step back instead of escalating
- Maintenance dosing and how long to stay on it
- Missed doses and travel
- FAQ
- Footer disclaimers
The standard 5-step semaglutide titration schedule
The Wegovy label and most compounded protocols use the same 5-step ladder:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Step | Weeks | Dose | Purpose |
|---|---|---|---|
| Step 1 | 1 to 4 | 0.25 mg | Tolerance, not therapeutic |
| Step 2 | 5 to 8 | 0.5 mg | First therapeutic dose |
| Step 3 | 9 to 12 | 1 mg | Mid-range |
| Step 4 | 13 to 16 | 1.7 mg | Pre-maintenance |
| Step 5 | 17 onward | 2.4 mg | Maintenance |
Total titration time is 16 weeks. Maintenance begins at week 17. Most patients can adjust the schedule by 2 to 4 weeks at any step if side effects are heavy, so the practical timeline runs 16 to 24 weeks before reaching 2.4 mg.
The 0.25 mg starter is below the threshold for meaningful weight loss. It exists to let the GI tract adapt. Patients who skip this step often experience nausea severe enough to discontinue. The 4-week starter window is the smallest investment that materially improves long-term tolerance.
Full dosage chart in mg, units, and mL
The unit and mL columns depend on the concentration of your specific vial. The most common compounded semaglutide concentrations are 2.5 mg/mL and 5 mg/mL.
| Dose (mg) | At 2.5 mg/mL: units | At 2.5 mg/mL: mL | At 5 mg/mL: units | At 5 mg/mL: mL |
|---|---|---|---|---|
| 0.25 mg | 10 units | 0.10 mL | 5 units | 0.05 mL |
| 0.5 mg | 20 units | 0.20 mL | 10 units | 0.10 mL |
| 1 mg | 40 units | 0.40 mL | 20 units | 0.20 mL |
| 1.7 mg | 68 units | 0.68 mL | 34 units | 0.34 mL |
| 2.4 mg | 96 units | 0.96 mL | 48 units | 0.48 mL |
Quick conversion math:
- At 2.5 mg/mL: divide the milligram dose by 2.5 to get mL, then multiply by 100 to get units. Or simply: units = mg × 40.
- At 5 mg/mL: divide the milligram dose by 5 to get mL, then multiply by 100. Or: units = mg × 20.
If your vial is a different concentration (some pharmacies use 1 mg/mL or 4 mg/mL), the math changes. Always verify by reading your vial label.
Why titration goes slowly
Semaglutide slows gastric emptying through GLP-1 receptor activation. The slowing is dose-dependent. Going from no dose to a therapeutic dose in one step would produce nausea severe enough to make most patients discontinue.
The 4-week interval between escalations exists for a measured reason. The body adapts to the slowed emptying over 2 to 3 weeks. Side effects peak in the first 7 to 14 days after a dose change and then improve. Adding 4 weeks per step gives time for adaptation plus a buffer.
A 2021 paper in The New England Journal of Medicine (Wilding et al., the STEP-1 trial) tracked nausea rates by dose week. Nausea peaked at 17.5% during the first 4 weeks at 0.25 mg and dropped to 8.6% by maintenance at 2.4 mg, even though the dose was almost ten times higher. Adaptation works.
Patients who pressure their providers to escalate faster usually pay for it with nausea, vomiting, and a higher discontinuation risk. The slow ladder is not arbitrary; it is the protocol with the lowest discontinuation rate and best long-term outcomes.
How concentration changes the unit count
Compounded semaglutide is not sold in fixed pens. It comes in a vial at a specified concentration, and patients draw the dose into a U-100 insulin syringe. The same milligram dose maps to different unit counts at different concentrations.
A worked example. Your prescription is 1 mg weekly.
- If your vial is 2.5 mg/mL: 1 mg = 0.4 mL = 40 units on a U-100 syringe
- If your vial is 5 mg/mL: 1 mg = 0.2 mL = 20 units
- If your vial is 1 mg/mL: 1 mg = 1.0 mL = 100 units (a full syringe)
- If your vial is 4 mg/mL: 1 mg = 0.25 mL = 25 units
Pharmacies use different concentrations depending on vial size and dispensing protocol. There is no universal "semaglutide unit count." The unit count is concentration-dependent.
When you switch pharmacies on a refill, always re-check the concentration before drawing the first dose. Drawing the same number of units at a new concentration delivers a different milligram dose.
Reading your vial label correctly
Concentration is printed on the vial label in one of three formats:
- "Semaglutide Injection 2.5 mg/mL" : the concentration is 2.5 mg per mL.
- "Semaglutide 25 mg / 10 mL Multi-Dose Vial" : divide 25 by 10 to get 2.5 mg/mL.
- "Semaglutide for Reconstitution, 10 mg" : this is a powder. The concentration is set when you mix it with bacteriostatic water per the pharmacy's instructions.
If the label shows only total milligrams without volume, the concentration is in the patient handout that came with the vial, in the prescription label on the outer box, or in the patient portal. Do not guess. Two pharmacies dispensing "10 mg vials" can use different total volumes, producing different concentrations.
If you cannot find the concentration anywhere, call the pharmacy before drawing a dose. A 5-minute phone call prevents a 5x dose error.
Pen doses (Wegovy) vs vial doses (compounded)
Brand-name Wegovy uses a fixed-dose pen system. Each pen contains 4 weekly doses at a single labeled strength.
| Wegovy pen | Strength per click | Doses per pen | Color |
|---|---|---|---|
| 0.25 mg pen | 0.25 mg fixed | 4 | Red |
| 0.5 mg pen | 0.5 mg fixed | 4 | Yellow |
| 1 mg pen | 1 mg fixed | 4 | Green |
| 1.7 mg pen | 1.7 mg fixed | 4 | Blue |
| 2.4 mg pen | 2.4 mg fixed | 4 | Purple |
Each pen lasts 4 weeks. When you escalate, you switch to the next pen color. There is no dial; the pen delivers exactly the labeled dose per click.
Compounded semaglutide uses a vial that you draw from with an insulin syringe. The same vial can supply multiple dose levels because the syringe selects the volume. A patient titrating from 0.25 mg to 2.4 mg may use the same multi-dose vial through several escalation steps before needing a new fill.
The clinical effect is the same molecule. The packaging and dosing experience are different. See our why compounded semaglutide is different for more on the compounded form.
When to hold or step back instead of escalating
The dosing chart shows the standard ladder. Real patients often deviate from it. Common reasons to hold or step back:
Reasons to extend the current dose by another 4 weeks:
- Persistent nausea more than mild
- Weight loss already strong at the current dose (over 1.5% per week sustained)
- Recent illness or hospitalization
- Travel that disrupts routine
- A1C or weight goal already achieved
Reasons to step back one level:
- Vomiting more than once per week
- Inability to maintain hydration
- Reflux that does not respond to OTC management
- New gallbladder symptoms
- Severe constipation despite fiber and fluid
Reasons to discontinue:
- Suspected pancreatitis
- Severe gastroparesis
- Pregnancy
- Allergic reaction
- Sustained inability to tolerate at any dose
The goal is not "reach 2.4 mg." The goal is sustainable weight loss with manageable side effects. Many patients respond well at 1 mg or 1.7 mg and never need to reach 2.4 mg. The ADA's 2024 Standards of Care explicitly endorse maintenance at the lowest effective dose.
Maintenance dosing and how long to stay on it
Once at 2.4 mg (or whichever dose produced satisfactory results), maintenance is indefinite. Semaglutide is not a "course of treatment" with an end date. It is a chronic medication for chronic weight management.
The STEP 5 trial (Garvey et al., Nature Medicine, 2022) followed patients on semaglutide 2.4 mg for 104 weeks. Mean weight loss was sustained at 15.2% from baseline. Patients who discontinued at week 68 regained two-thirds of their lost weight within 12 months.
The implication: stopping semaglutide usually causes weight regain. Patients who plan to stop should plan for the regain or have a different intervention ready.
Some patients reduce to a lower maintenance dose (1.7 mg or 1 mg) once weight is stable. The data on lower-dose maintenance is limited but suggests partial weight regain compared to staying at 2.4 mg. The trade-off is fewer side effects and lower cost.
A small number of patients try alternate-week dosing (2.4 mg every 14 days instead of every 7). This is off-label and underdocumented. It may work for some, but published evidence is thin.
Missed doses and travel
Missed dose under 5 days late: take it as soon as you remember. Resume your normal weekly schedule from there. Semaglutide's half-life is about 7 days, so a small timing shift does not matter much.
Missed dose 5 or more days late: skip the missed dose. Take your next dose on your regular weekly day. Do not double up. If three or more weeks pass without a dose, you may need to step back one level on the ladder when you restart, because the body partially loses its tolerance.
Travel across time zones: semaglutide is dosed weekly. A 6-hour or 12-hour shift does not matter. Take your dose on the same calendar day of the week, local time.
Switching the day of the week: allowed as long as the gap is at least 48 hours and not more than 9 days from the prior dose.
Travel storage: vials and pens both need refrigeration before first use. Once a Wegovy pen is in use, it is good at room temperature for up to 28 days. Compounded semaglutide vials, once punctured, are typically good for 28 days refrigerated. Insulated travel cases with gel packs (not direct ice) work for trips up to 24 hours. For longer trips, pack to keep medication between 36 and 46°F.
FAQ
What is the maximum semaglutide dose for weight loss? 2.4 mg once weekly. This is the FDA-approved Wegovy maintenance dose and the standard target dose for compounded semaglutide weight-loss protocols. Doses above 2.4 mg have not been shown to produce additional weight loss.
How long until I reach 2.4 mg of semaglutide? 17 weeks if you escalate every 4 weeks without holds. The standard ladder is 0.25 mg (weeks 1-4), 0.5 mg (weeks 5-8), 1 mg (weeks 9-12), 1.7 mg (weeks 13-16), and 2.4 mg (week 17 onward). Most real patients take 18 to 24 weeks because of one or more dose holds for tolerance.
How many units is 0.25 mg of semaglutide? At 2.5 mg/mL it is 10 units on a U-100 insulin syringe. At 5 mg/mL it is 5 units. At 1 mg/mL it is 25 units. The unit count depends on your vial concentration.
How many units is 2.4 mg of semaglutide? At 2.5 mg/mL it is 96 units. At 5 mg/mL it is 48 units. Always confirm against your specific vial concentration before drawing.
Can I escalate faster than every 4 weeks? Not safely. The 4-week interval allows the GI tract to adapt to slowed gastric emptying. Faster escalation produces severe nausea and vomiting in most patients. Some providers extend escalation intervals to 6 or 8 weeks if side effects are heavy, but shortening them is not recommended.
Why is my unit count different from my friend's? Almost certainly because your vials are at different concentrations. A 1 mg dose is 40 units at 2.5 mg/mL and 20 units at 5 mg/mL. The same milligram dose maps to different unit counts at different concentrations. Read your vial label.
Can I split my weekly dose into smaller injections? Semaglutide's half-life is about 7 days, so weekly dosing is the established schedule. Splitting into two doses per week halves each injection's volume but keeps the weekly total. Some patients do this during titration to soften side effects. Discuss with your provider before splitting.
What happens if I draw too much semaglutide? Push the excess back into the vial before injecting. Do not inject extra. If you have already injected, expect heightened nausea and possible vomiting. Hydrate. Skip the next scheduled dose. Resume your normal schedule one full week after the over-dose. Call a provider if symptoms are severe.
Do I need a prescription to draw semaglutide from a vial? Yes. Semaglutide is a prescription medication regardless of whether it is dispensed as a brand-name pen or a compounded vial. Compounded semaglutide must be prescribed by a licensed provider and dispensed by a state-licensed compounding pharmacy.
Is the dosing chart different for diabetes? Yes. Ozempic (the diabetes-labeled semaglutide product) tops out at 2 mg. Wegovy (the weight-loss-labeled product) goes to 2.4 mg. The ladder is similar but the maximum is different. Compounded semaglutide protocols vary; for weight management they typically follow the Wegovy ladder.
What size syringe should I use? For semaglutide draws under 50 units, a 0.3 mL U-100 insulin syringe with 0.5-unit markings is preferred for accuracy. For larger draws (over 50 units, e.g., 1.7 mg or 2.4 mg at 2.5 mg/mL), a 1 mL U-100 syringe is standard. The needle is typically 31-gauge, 5/16-inch.
Can I round my dose up or down? Rounding by 1 to 2 units in either direction is generally clinically irrelevant for semaglutide. Do not round up by more than 2 units without confirming with your provider. Rounding down is safer if you are unsure between two markings.
How long does compounded semaglutide last in the vial? A typical compounded vial lasts 28 days after first puncture if refrigerated. Some pharmacies stamp 21 days. Discard the vial after the stamped date even if liquid remains.
Does the dosing chart change if I have kidney or liver disease? The label does not require dose adjustments for mild to moderate kidney or liver impairment. Severe impairment is a relative contraindication. Patients with kidney disease should be monitored more closely because GI side effects (vomiting, dehydration) can worsen kidney function acutely.
Author / review note
Reviewed by the FormBlends Medical Team. References include the Wegovy prescribing information (rev. 2024), Wilding et al., The New England Journal of Medicine, 2021 (STEP-1 trial), Garvey et al., Nature Medicine, 2022 (STEP-5 trial), the U.S. Pharmacopeia chapter on insulin syringes, and the American Diabetes Association Standards of Care 2024.
Sources
- The Wegovy prescribing information (rev. 2024).
- Wilding et al., The New England Journal of Medicine, 2021 (STEP-1 trial).
- Garvey et al., Nature Medicine, 2022 (STEP-5 trial).
- The U.S. Pharmacopeia chapter on insulin syringes.
- The American Diabetes Association Standards of Care 2024.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →